Source link : https://www.newshealth.biz/health-news/fda-approves-bvr2-combo-for-r-r-lbcl/
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris; Seagen, Inc., a Pfizer subsidiary), in combination with lenalidomide and rituximab, for adults with large B-cell lymphoma that recurs or fails to respond to at least two prior lines of therapy. Approval, based on response rates and […]
Author : News Health
Publish date : 2025-02-12 20:28:55
Copyright for syndicated content belongs to the linked Source.